Ben-Gurion
University of the Negev (BGU) scientists revealed that a large number of
children affected by Obstructive Sleep Apnea (OSA) treated with montelukast, a
drug given approval for asthma or hay fever, confirmed significant development
in respiratory interference and adenoid size, based on a new study posted in
Pediatrics Journal.
A
big percentage of children that suffer from OSA and bear tonsillectomies and
polypectomies frequently end up having post-operative infection, bleeding and
dehydration. Some young kids go through a reoccurrence of the problem.
Based
on Dr. Aviv Goldbart, a researcher in BGU's Faculty of Health Sciences, "Our aspiration is to find non-invasive
therapies for OSA. We are actually seeking a nonsurgical therapy which will be
used in comparison to tonsillectomies and polypectomies in children, and also
as a replacement for continuous positive airway pressure (CPAP) machines for
grown-ups."
The
research was examined in a double-blind, randomized, placebo-controlled fashion
wherein 23 young kids received placebos, and 23 children received montelukast.
After a 12-week therapy with daily oral doses, young kids experienced reduced
severity of OSA. These same 23 children also showed significant development in
respiratory disturbance, adenoid size and children's indications. The
obstructive apnea index appeared to be decreased by over 50 percent in 65
percent of treated young kids.
No comments:
Post a Comment